Oncolytic virus - Vyriad

Drug Profile

Oncolytic virus - Vyriad

Alternative Names: vesicular stomatitis virus - Vyriad; VSV oncolytic virus - Vyriad

Latest Information Update: 06 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Omnis Pharma
  • Developer Mayo Clinic; Vyriad
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatocellular carcinoma; Liver metastases
  • Preclinical Head and neck cancer

Most Recent Events

  • 12 Jan 2015 Phase-I clinical trials in Liver metastases in USA (Parenteral)
  • 12 Jan 2015 Omnis and MedImmune enter into a licensing agreement for development of oncolytic viruses in the treatment of cancer
  • 12 Jan 2015 Phase-I clinical trials in Hepatocellular carcinoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top